Tadalafil 20 mg + Dapoxetine 60 mg combines a long‑acting PDE5 inhibitor with a short‑acting SSRI to address erectile dysfunction and premature ejaculation in one on‑demand regimen, pairing corpus cavernosum smooth‑muscle relaxation via cGMP enhancement with central serotonergic modulation to delay ejaculation. Pharmacokinetic work shows dapoxetine 60 mg has no clinically meaningful interaction with tadalafil 20 mg, supporting coordinated coadministration when clinically indicated. Small randomized and observational studies suggest combination therapy (typically tadalafil 5–10 mg with dapoxetine 30 mg) improves intravaginal ejaculatory latency and satisfaction compared with either agent alone, though higher‑dose pairings should be individualized.